0001104659-23-041280.txt : 20230404 0001104659-23-041280.hdr.sgml : 20230404 20230404102545 ACCESSION NUMBER: 0001104659-23-041280 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230404 DATE AS OF CHANGE: 20230404 EFFECTIVENESS DATE: 20230404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lennham Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001853301 IRS NUMBER: 833016066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-477817 FILM NUMBER: 23795572 BUSINESS ADDRESS: STREET 1: 53 MAIN STREET STREET 2: SUITE 206 CITY: CONCORD STATE: MA ZIP: 01742 BUSINESS PHONE: 6173887171 MAIL ADDRESS: STREET 1: 53 MAIN STREET STREET 2: SUITE 206 CITY: CONCORD STATE: MA ZIP: 01742 D 1 primary_doc.xml X0708 D LIVE 0001853301 Lennham Pharmaceuticals, Inc. 53 MAIN STREET SUITE 206 CONCORD MA MASSACHUSETTS 01742 617 388-7171 DELAWARE None None Corporation true 2019 Bradford C. Sippy 53 Main Street Suite 206 Concord MA MASSACHUSETTS 01742 Executive Officer Director Benjamin D. Enerson 53 Main Street Suite 206 Concord MA MASSACHUSETTS 01742 Executive Officer Corey MacGregor 53 Main Street Suite 206 Concord MA MASSACHUSETTS 01742 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2021-10-28 false true false 50000 1200000 1200000 0 Offering and sales amounts consist of convertible note investments with an aggregate principal amount of $1,200,000. false 13 0 0 0 false Lennham Pharmaceuticals, Inc. /s/ Bradford C. Sippy Bradford C. Sippy CEO 2023-04-03